248
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Race (and ethnicity) matters in myelodysplastic syndromes

&
Pages 1519-1521 | Received 07 Apr 2022, Accepted 07 Apr 2022, Published online: 28 Apr 2022

References

  • West C. Race matters. Boston: Beacon Press; 1993.
  • Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247.
  • Negoro E, Nagata Y, Clemente MJ, et al. Origins of myelodysplastic syndromes after aplastic anemia. Blood. 2017;130(17):1953–1957.
  • Komrokji R, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91(5):E280–283.
  • Iwanaga M, Hsu W-L, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428–434.
  • Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658–670.
  • Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39(33):3737–3746.
  • Abraham I, Rauscher G, Patel A, et al. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022;139(14):2212–2226.
  • Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in african americans and whites with acute myeloid leukemia. Blood. 2004;103(11):4036–4042.
  • Brady A, Fu A, Earl M, et al. Race and intensity of post-remission therapy in acute myeloid leukemia. Leuk Res. 2011;35(3):346–350.
  • Nazha A, Al-Issa K, Przychodzen B, et al. Differences in genomic patterns and clinical outcomes between African-American and white patients with myelodysplastic syndromes. Blood Cancer J. 2017;7(9):e602.
  • Goksu SY, Ozer M, Goksu BB, et al. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leuk Lymphoma. 2022;1–9. 10.1080/10428194.2022.2032034?journalCode=ilal20.
  • Overview of the SEER Program: National Cancer Institute. Available from: https://seer.cancer.gov/about/overview.html.
  • Miyazaki Y, Tuechler H, Sanz G, et al. Differing clinical features between japanese and caucasian patients with myelodysplastic syndromes: Analysis from the international working group for prognosis of MDS. Leuk Res. 2018;73:51–57.
  • Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol. 2006;24(34):5358–5365.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.